AUSTIN,
Texas, July 1, 2024 /PRNewswire/ -- Aileron
Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a
biopharmaceutical company advancing a novel pipeline of
first-in-class medicines to address significant unmet medical needs
in orphan pulmonary and fibrosis indications, today announced that
the Company is set to join the Russell Microcap® Index
at the conclusion of the 2024 Russell U.S. Indexes annual
reconstitution, effective at the open of US equity markets on
Monday, July 1, 2024.
The annual Russell U.S. Indexes reconstitution captures the
4,000 largest U.S. stocks as of Tuesday,
April 30th, ranking them by total market capitalization.
Membership in the Russell Microcap® Index, which remains in place
for one year, means automatic inclusion in the appropriate growth
and value style indexes. FTSE Russell determines membership for its
Russell indexes primarily by objective, market-capitalization
rankings and style attributes.
"Aileron's inclusion in the Russell Microcap Index is an
exciting step in the Company's evolution, and representative of the
clinical progress made for our lead asset, LTI-03, in patients with
idiopathic pulmonary fibrosis," said Brian
Windsor, Ph.D., President and Chief Executive Officer of
Aileron. "This increased exposure highlights our positive data
reported from Cohort 1 of the Phase 1b trial which included biomarker movement which
achieved statistical significance in three out of eight markers
that reinforce the potential of LTI-03 to improve lung function and
reverse the course of the disease."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Russell's U.S. indexes serve as the
benchmark for about $10.5 trillion in
assets as of the close of December
2023. Russell indexes are part of FTSE Russell, a leading
global index provider.
For more information on the Russell Microcap® Index and the
Russell indexes reconstitution, go to the "Russell Reconstitution"
section on the FTSE Russell website.
About Aileron Therapeutics
Aileron Therapeutics, Inc. is a biopharmaceutical company
advancing a novel pipeline of first-in-class medicines to address
significant unmet medical needs in orphan pulmonary and fibrosis
indications. Aileron's lead product candidate, LTI-03, is a novel,
synthetic peptide with a dual mechanism targeting alveolar
epithelial cell survival as well as inhibition of profibrotic
signaling. Currently, LTI-03 is being evaluated in a Phase
1b clinical trial for the treatment
of idiopathic pulmonary fibrosis. Aileron's second product
candidate, LTI-01, is a proenzyme that has completed Phase
1b and Phase 2a clinical trials for
the treatment of loculated pleural effusions. LTI-01 has received
Orphan Drug Designation in the US and EU and Fast Track Designation
in the US.
About FTSE Russell
FTSE Russell is a leading global
provider of benchmarking, analytics, and data solutions for
investors, giving them a precise view of the market relevant to
their investment process. A comprehensive range of reliable and
accurate indexes provides investors worldwide with the tools they
require to measure and benchmark markets across asset classes,
styles, or strategies.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. For over 30 years,
leading asset owners, asset managers, ETF providers and investment
banks have chosen FTSE Russell indexes to benchmark their
investment performance and create ETFs, structured products, and
index-based derivatives.
FTSE Russell is focused on applying the highest industry
standards in index design and governance, employing transparent
rules-based methodology informed by independent committees of
leading market participants. FTSE Russell fully embraces the IOSCO
Principles, and its Statement of Compliance has received
independent assurance. Index innovation is driven by client needs
and customer partnerships, allowing FTSE Russell to continually
enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit
https://www.lseg.com/en/ftse-russell.
Investor Relations & Media Contact:
Argot
Partners
aileron@argotpartners.com
212-600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aileron-therapeutics-to-be-included-in-the-russell-microcap-index-302185942.html
SOURCE AILERON THERAPEUTICS